hrp0086fc3.6 | Pituitary | ESPE2016

Pegvisomant is More Effective in Stunting Growth than Somatostatin Analogs in Childhood Acromegaly/Gigantism

Thomas-Teinturier Cecile , Simonin Gilbert , Vaczlavik Anna , Ajaltouni Zaina , Gaillard Stephan , Bougneres Pierre , Chanson Philippe

Background: We describe our experience in medical therapy for invasive somatotroph pituitary macroadenomas in 8 children or adolescents presenting with acromegaly/gigantism, in terms of growth and IGF-I levels control.Patients: Eight children, aged 5 to 17 years (median 12.4 years), presented with growth hormone (GH) hypersecretion related to somatotroph pituitary macroadenomas with cavernous sinus invasion in 6/8. Genetic testing revealed AIP mutation i...

hrp0084p3-585 | Adrenals | ESPE2015

Living with Adrenal Hyperplasia for Children in Primary School between 6 and 11 Years; Educational Innovation and Design of a Learning Tool for Therapeutic Education

Pienkowski Catherine , Cartault Audrey , Durand Adelaide , Ajaltouni Zeina , Jouret Beatrice , Tauber Maithe

Background: Congenital adrenal hyperplasia (CAH) is a rare chronic disease diagnosed and treated from birth. Hormone replacement therapy is essential to lead a normal life and must be adapted to stress. Poor compliance to treatment or inefficacy is life threatening leading to high risk of by dehydration and hypoglycaemia.Objective: The objective of therapeutic education sessions is based on the skills needed for regular intake of pills and recognition of...